Medpace Holdings, Inc. (MEDP) Price History:53.47%(TTM)
Over the latest trailing 12-month period, Medpace Holdings, Inc. (MEDP)'s price cagr is +53.47%. The comparable SPY value is +24.52%. Year-to-date price return is -19.95%. Price CAGR uses adjusted close price history and excludes dividends.
Current Price
$457.09
$-4.51 (-0.98%)
Previous Close: $461.60
Last Session
- Open
- $457.10
- Day High
- $466.68
- Day Low
- $455.02
- Volume
- 240.05K
- Avg Volume
- 363.91K
52-Week Position
49%
of the 52-week price range
- From 52-week high
- -27.32%
- From 52-week low
- +55.44%
52-Week Price Range
52-Week Low
$294.07
Jun 18, 2025
Current Price
$457.09
49% of range
52-Week High
$628.92
Jan 21, 2026
Price Returns by Period
1 Day
-0.98%
7 Days
-1.86%
30 Days
+8.66%
YTD
-19.95%
1 Year
+53.43%
vs 52W High
-27.32%
MEDP Price Chart
Long-Term Performance (CAGR)
Price CAGR (3Y)
+27.22%
Price CAGR (5Y)
+20.25%
Total Return CAGR (3Y)
+27.22%
Total Return CAGR (5Y)
+20.25%
CAGR (Compound Annual Growth Rate) shows the annualized return over the specified period. Total Return includes dividends reinvested.
Key Price Statistics
| Current Price | $457.09 |
| Previous Close | $461.60 |
| Day Range | $455.02 - $466.68 |
| 52-Week Range | $294.07 - $628.92 |
| Volume | 240.05K |
| Average Volume | 363.91K |
| Market Cap | $13.05B |
| % from 52W High | -27.32% |
Related Metrics
About Medpace Holdings, Inc.
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- August James Troendle